Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are recommended for glycaemic
management in patients with type 2 diabetes (T2D). Oral semaglutide, the first oral GLP …

Aim Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …

In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor
management reduces the likelihood of late-stage diabetic complications. Guidelines …

Oral semaglutide (Rybelsus®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-
1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral …

Aim To assess the efficacy and safety of oral semaglutide, a novel glucagon‐like peptide‐1
receptor agonist, for patients with type 2 diabetes. Methods We searched Medline, Embase …

Introduction This post hoc pooled analysis of four real-world studies (SURE Canada,
Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) …

Early and effective glycemic control can prevent or delay the complications associated with
type 2 diabetes (T2D). The benefits of glucagon-like peptide-1 receptor agonists (GLP …

Aim Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA)
indicated for glycaemic management in adults with type 2 diabetes (T2D). Oral semaglutide …

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering
hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class …

Background Semaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) analogue for
type 2 diabetes. Few clinical trials have reported on the concomitant use of GLP-1 receptor …